Missoula, MT — March 29, 2026 — Inimmune, a biotechnology company advancing next-generation vaccine adjuvants and immunotherapies, today announced that its leadership team will present new data and insights at the World Vaccine Congress (WVC) in Washington, DC, from March 30 to April 2, 2026.
CEO David Burkhart, Ph.D., will chair the “Vaccine Technology Workshop” on March 30 (Room 202, Level 2). That same day, Shannon Miller, Ph.D., VP of Operations, will present on the clinical development of a TLR4 agonist currently in Phase 2 trials for allergic rhinitis.
Chief Scientific Officer Jay Evans, Ph.D., will join the “Adjuvants and Immunity” panel on March 30 and moderate the April 2 session, “Genetic Adjuvants & mRNA Vaccine Durability: Next-Gen Strategies for Enhanced Immune Response.”
Juhienah Khalaf, Ph.D., Director of Chemistry, will co-present with Peter Tygesen of SPI Pharma in the “Innovative Adjuvants for Global Health” session, highlighting collaborative efforts to develop affordable, accessible adjuvant systems and providing updates on Inimmune’s expanding pipeline.
Across these sessions, Inimmune will showcase progress in its portfolio of immunomodulators and adjuvant platforms, underscoring its focus on enabling more precise, effective immune responses for vaccines and standalone therapies.
“Inimmune is proud to join global leaders at this year’s World Vaccine Congress,” said Dr. Burkhart. “We’re excited to share advancements in innate immune modulation, adjuvant and delivery technologies that can help accelerate immunological innovation and enable new partnerships.”
The company recently completed a Phase 1a/1b trial of INI-2004, a TLR4 agonist for allergic rhinitis, and has initiated a Phase 2 study in January 2026, with topline data reading out in June
